Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination | Zendy

Pierre Vandepapelière | Zendy; R Barrasso | Zendy; Chris J.L.M. Meijer | Zendy; Jan M.M. Walboomers | Zendy; Martine Wettendorff | Zendy; Lawrence R. Stanberry | Zendy; Charles Lacey | Zendy

Open Access

Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination

Author(s) -

Pierre Vandepapelière,

R Barrasso,

Chris J.L.M. Meijer,

Jan M.M. Walboomers,

Martine Wettendorff,

Lawrence R. Stanberry,

Charles Lacey

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/498164

Subject(s) - human papillomavirus , medicine , vaccination , hpv infection , genital warts , virology , randomized controlled trial , immunology , cervical cancer , cancer , human immunodeficiency virus (hiv) , syphilis

Cellular immunity is involved in spontaneous clearance of anogenital warts caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept of therapeutic vaccination. A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research